SNCA and Parkinson disease: In addition, a second GCase modulator, NCGC00188758 [106], effectively increased α-synuclein clearance in dopaminergic neurons differentiated from iPSc derived from PD patients; notably, the patients studied included both idiopathic PD and PD caused by mutations in α-synuclein (SNCA) (triplication or A53T) or ATPase13A2 (PARK9) genes.